In a PK→PD model, duration by ED severity can be represented as a parameter-set context in which severity-related variation is encoded through absorption rate, distribution kinetics, metabolic turnover, elimination geometry, and PD persistence mapping. Duration is defined here as the modeled interval during which concentration remains within a specified PD persistence region, rather than as a clinical effect. Sildenafil and tadalafil can be represented by different baseline parameter sets: sildenafil with a comparatively steeper rise and shorter decline, tadalafil with a more gradual rise and longer decline. Severity-related variation expands the parameter space around those trajectories without assigning clinical categories or outcomes. A duration difference is therefore a geometric property of the concentration–time curve after PK parameters and PD boundaries are specified. The persistence interval depends on how quickly exposure develops, redistributes, turns over, and declines relative to the selected PD mapping. See the duration versus onset balance framework.
PK determinants shape duration through distinct parts of the concentration–time trajectory. Absorption geometry primarily establishes early exposure and can indirectly affect the later position of the trajectory relative to a persistence region. Distribution kinetics influence movement among compartments, while metabolic turnover removes parent compound and contributes to the transition from peak exposure toward later concentrations. Elimination rate controls much of the descending geometry: slower effective elimination produces a more gradual decline, whereas faster elimination compresses the persistence interval. Severity-based parameter sets can therefore differ even when absorption parameters are identical. Two modeled trajectories with the same early rise can diverge later if distribution, turnover, or elimination parameters differ. Tmax provides a time coordinate for peak concentration, and Cmax provides a peak magnitude, but neither independently defines duration. They are contextual descriptors of peak geometry, while persistence depends on the later trajectory relative to the selected PD region.
PD mapping determines how a concentration trajectory is converted into a modeled persistence interval. A persistence threshold defines the concentration coordinate at which the trajectory is considered to remain inside a specified PD region. If that threshold shifts upward, the descending curve crosses it earlier; if it shifts downward, the same curve remains inside the region longer. Severity-based PD variability can therefore change duration coordinates without changing the underlying PK trajectory. Conversely, PK variability can alter the trajectory while the PD threshold remains fixed. These sources of variation can interact, producing different modeled persistence intervals from combinations of concentration-time geometry and threshold placement. Sildenafil and tadalafil can be represented within the same framework while retaining different PK parameter sets for absorption, distribution, turnover, and elimination. The comparison remains mechanistic: it describes where trajectories intersect persistence boundaries. ED severity is therefore only a label for parameter-set variability, not a clinical category or outcome measure. The PK→PD summary framework integrates these relationships.
Severity-based absorption variability can be represented as changes in the input function that establish the early concentration trajectory. A faster absorption rate produces a steeper initial rise, while a slower rate distributes systemic input across a longer interval. This changes the concentration available for later distribution, metabolism, and elimination, so absorption can influence persistence indirectly even though duration is primarily determined by the later trajectory. Two parameter sets can therefore share the same elimination rate yet produce different concentration-time profiles because their early input geometry differs. Conversely, identical absorption parameters can be paired with different elimination parameters, producing similar rising phases but different persistence intervals. In a mechanistic model, severity-related variation is simply a way to organize these alternative parameter sets. It does not imply a separate absorption mechanism. The relevant geometric consequence is movement of the concentration curve relative to the eventual persistence region, with the early phase establishing the starting conditions for the later decline.
Distribution and metabolic turnover variability directly modify the later concentration trajectory. Distribution kinetics determine how exposure moves between compartments and can introduce distinct early, intermediate, or terminal phases. Metabolic turnover controls the removal of parent compound and contributes to the rate at which concentration falls after systemic input decreases. If distribution is slower, the trajectory can display a more extended redistribution phase; if turnover is slower, the parent concentration can decline more gradually. Elimination then governs the net downward movement once these processes combine. Severity-based parameter sets can encode differences in any of these terms without changing the underlying model structure. Two trajectories may therefore have comparable absorption geometry but different persistence because their distribution, metabolic turnover, or elimination parameters differ. The resulting duration interval is calculated from the trajectory’s intersection with a specified persistence boundary. PK variability consequently changes duration through changes in curve shape, slope, phase structure, and terminal decline.
| PK Domain | Mechanistic Determinant | Link |
|---|---|---|
| Absorption | Early exposure geometry. | absorption curves |
| Distribution & Metabolism | Persistence geometry. | pk variability |
A PD persistence threshold defines the concentration region used to translate exposure into a modeled duration coordinate. The threshold can be represented as a fixed boundary on the concentration axis, with the duration interval ending when the descending trajectory crosses that boundary. Severity-based PD variability can be modeled by shifting the boundary relative to an unchanged PK curve. A higher boundary is crossed sooner during decline, while a lower boundary is crossed later. This means that the same concentration-time trajectory can generate different duration coordinates under different PD mappings. The PK curve itself has not changed; only the concentration-to-PD interpretation has changed. The model therefore separates pharmacokinetic geometry from pharmacodynamic threshold placement. Persistence mapping can be applied identically to sildenafil and tadalafil while preserving their distinct concentration-time parameter sets. The resulting duration coordinate reflects the intersection between each PK trajectory and its assigned persistence region, without assigning a clinical meaning to the modeled threshold.
PD variability can modify duration even when the underlying PK trajectory is held constant. Consider a fixed concentration-time curve with two alternative persistence boundaries. The first boundary may intersect the descending curve at an earlier time coordinate, while the second intersects it later. The resulting duration values differ despite identical absorption, distribution, metabolic turnover, and elimination parameters. In a severity-based model, such threshold shifts can represent variation in the PD mapping associated with different parameter sets. This does not alter the PK curve or its elimination geometry. Conversely, a fixed PD threshold can be combined with different PK trajectories to isolate the contribution of pharmacokinetic variability. The two dimensions can then be analyzed independently or jointly. Duration is therefore not determined by concentration alone; it depends on concentration-time geometry and the rule used to map concentration into a persistence region. This framework allows PD variability to be represented as threshold displacement rather than as a clinical classification.
| PD Domain | Mechanistic Determinant | Link |
|---|---|---|
| Persistence Threshold | Concentration–effect mapping. | pd variability |
| PD Variability | Duration differences. | pkpd summary |
PK trajectories determine persistence geometry through the combined behavior of absorption, distribution, metabolic turnover, and elimination. Under severity-based parameter variability, each of these terms can be assigned alternative values while preserving the same structural model. Absorption determines how quickly systemic exposure develops, distribution shapes compartmental movement, metabolic turnover contributes to parent-compound removal, and elimination controls much of the terminal decline. The resulting trajectory can be compared with a fixed PD persistence boundary to determine its duration coordinate. Sildenafil and tadalafil can occupy different baseline parameter regions within this framework: sildenafil can be modeled with a steeper rise and faster decline, whereas tadalafil can be modeled with a more gradual rise and slower decline. Severity-based variability then broadens each parameter set rather than creating a separate mechanism. The speed profile is therefore a compact representation of exposure development and decline, with persistence emerging from the later portion of the trajectory.
PD mapping determines the location of the persistence boundary against which a PK trajectory is interpreted. A concentration-time curve contains no duration coordinate by itself; the duration coordinate appears only after a PD region has been specified. The threshold can be placed at a selected concentration level, and the descending trajectory can then be followed until it crosses that level. Severity-based PD variability can shift this boundary while leaving the underlying PK parameters unchanged. The same principle applies when comparing sildenafil and tadalafil: their distinct concentration-time trajectories can be evaluated against a common conceptual persistence map, or each can be evaluated against parameter-specific PD mappings. Onset-related coordinates remain separate because the persistence boundary concerns the later trajectory rather than the initial entry phase. This separation allows duration geometry to be analyzed without treating duration as a direct proxy for any clinical outcome. The resulting interpretation is a mathematical mapping between exposure and a predefined PD region.
PK and PD variability interact when both the concentration trajectory and the persistence boundary change between parameter sets. A PK change can alter the slope, curvature, or terminal position of the concentration-time curve, while a PD change can move the boundary used to define persistence. If both change in the same modeled direction, the duration coordinate can shift more substantially than either change alone; if they shift in opposing directions, the effects can partially offset. This interaction can be used to represent severity-associated parameter sets without defining severity as a clinical category. Sildenafil and tadalafil provide distinct baseline trajectories, and each trajectory can then be combined with alternative absorption, distribution, turnover, elimination, and PD mappings. The resulting duration values are therefore properties of combined parameter sets. The framework keeps PK geometry and PD interpretation conceptually separate while allowing them to interact mathematically. Duration is the final coordinate produced by their intersection, not an independent property assigned to a severity label.
| Balance Domain | Mechanistic Determinant | Link |
|---|---|---|
| PK Trajectory | Exposure development. | speed profiles |
| PD Mapping | Threshold placement. | onset difference |
| PK→PD Balance | Combined geometry. | duration vs onset balance |
Duration by ED severity can be represented as a PK→PD parameter-set problem. Each severity-labeled context can be assigned values for absorption rate, distribution kinetics, metabolic turnover, elimination rate, and PD persistence threshold. The resulting parameters generate a concentration-time trajectory, and duration is calculated as the interval during which that trajectory remains within the persistence region. Two contexts can therefore have different duration coordinates because their PK curves differ, their PD boundaries differ, or both differ. The severity label does not itself cause a duration change in the model. It identifies a particular parameter set. Sildenafil and tadalafil can each be assigned baseline PK profiles, after which additional parameter variability can be introduced. This approach treats duration as a geometric coordinate produced by PK trajectory and PD mapping.
PK parameters shape severity-based duration by changing the concentration-time trajectory. Absorption rate establishes early input geometry, while distribution kinetics determine how exposure moves between compartments. Metabolic turnover removes parent compound and influences the transition toward lower concentrations. Elimination rate affects the descending phase, with slower elimination producing a more gradual decline and faster elimination producing a steeper decline. Two parameter sets can therefore have identical absorption but different duration if their elimination rates differ. Different absorption profiles can also alter the trajectory while elimination remains identical. Tmax and Cmax describe peak timing and magnitude, but they do not independently establish the persistence interval. Duration is determined by the trajectory relative to a PD boundary. In a severity-based model, the severity label organizes PK parameter combinations rather than functioning as an independent variable.
PD parameters influence duration by determining how concentration is mapped into a persistence region. A threshold establishes the concentration boundary used to define persistence. If the boundary is positioned higher, the descending concentration curve reaches it earlier. If the boundary is positioned lower, the same curve remains within the defined region longer. Two parameter sets can therefore share the same PK trajectory yet produce different duration coordinates because their PD mappings differ. This is distinct from variability in absorption, distribution, turnover, or elimination. In a severity-based framework, PD variability can be represented as threshold displacement while PK geometry remains unchanged. Alternatively, the PD boundary can remain fixed while PK parameters vary. The dimensions can then be combined to describe a complete PK→PD duration coordinate without requiring a clinical category for the mathematical representation.
Sildenafil and tadalafil can be represented by different duration geometries because their baseline PK parameter sets differ. In a simplified model, sildenafil can have a steeper absorption phase and faster decline, while tadalafil can have a more gradual absorption phase and slower decline. The rising-phase difference affects how the trajectory develops before its persistence region is reached, whereas elimination primarily affects the later persistence segment. Parameter variation can then modify absorption, distribution, metabolic turnover, elimination, or PD threshold placement around either baseline profile. Two modeled contexts can therefore produce different duration coordinates without changing the model structure. Each concentration-time curve intersects a defined persistence boundary at a particular point. Duration is the resulting interval, not a property of the severity label. The model separates compound-specific PK parameters from variability represented by severity-associated parameter sets.
PK→PD variability expands duration interpretation by allowing the concentration trajectory and persistence mapping to vary. PK parameters can alter absorption slope, distribution phases, metabolic turnover, and elimination, producing different concentration-time curves. PD parameters can independently shift the persistence threshold used to convert those curves into duration coordinates. When both dimensions vary, the resulting interval reflects their combined geometry. A severity label can therefore represent a family of parameter sets rather than a single trajectory. Within that family, differences may originate mainly from elimination, distribution, turnover, or threshold placement. Sildenafil and tadalafil can be modeled with baseline trajectories before this variability is introduced. The framework treats severity-associated variation as a way to explore how PK and PD parameters alter persistence geometry. Duration is the mathematical output of that combined mapping.